Given Imaging target raised to $20 from $18 at Needham
Needham raised its target on Given Imaging after the company released clinical data on the Pillcam Colon2 product, which exceeded the firm's expectations. Needham keeps a Buy rating on shares. :theflyonthewall.com
News For GIVN From The Last 14 Days
Check below for free stories on GIVN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
